Posted by Michael Wonder on 19 Nov 2020
Pacira receives European Commission approval for Exparel (bupivacaine liposome injectable suspension) for the treatment of post-surgical pain
18 November 2020 - Approval based on four pivotal studies showing Exparel reduced pain scores and opioid use following surgery.
Pacira BioSciences today announced that the European Commission has granted marketing authorisation for Exparel as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults.
